Tamoxifen evolution.
作者信息
Howell A, Howell S J
机构信息
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Prevent Breast Cancer Centre, Wythenshawe Hospital Manchester Universities Foundation Trust, Wythenshawe, Manchester, UK.
出版信息
Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.
Abstract
摘要
相似文献
1
Tamoxifen evolution.
Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.
2
The limits of tamoxifen.
Ir J Med Sci. 2002 Jan-Mar;171(1):8-9. doi: 10.1007/BF03168929.
3
Breast cancer patients can stop tamoxifen after 5 years.
West J Med. 2001 Jul;175(1):13. doi: 10.1136/ewjm.175.1.13.
4
Tamoxifen reduces breast cancer by a third in high risk women.
BMJ. 2002 Sep 21;325(7365):613. doi: 10.1136/bmj.325.7365.613/a.
5
Tamoxifen for the treatment and prevention of breast cancer: an update.
Plast Surg Nurs. 2000 Winter;20(4):234-6. doi: 10.1097/00006527-200020040-00010.
6
Tamoxifen for early breast cancer.
Nurs Times. 2001;97(25):41.
7
Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
.
Int J Clin Pharmacol Ther. 2017 Aug;55(8):690-691. doi: 10.5414/CPXCES15EA05.
8
[Adjuvant tamoxifen treatment in breast cancer: is 5-year treatment sufficient?].
Ugeskr Laeger. 1997 Jun 16;159(25):3968-9.
9
CYP2D6 genotype and adjuvant tamoxifen.
Clin Pharmacol Ther. 2014 Aug;96(2):138-40. doi: 10.1038/clpt.2014.96.
10
Adjuvant treatment with tamoxifen. Care is necessary.
BMJ. 1996 Aug 24;313(7055):493-4. doi: 10.1136/bmj.313.7055.493c.
引用本文的文献
1
Therapeutic resistance and combination therapy for cancer: recent developments and future directions.
Sci Rep. 2025 Jul 24;15(1):26881. doi: 10.1038/s41598-025-12725-w.
2
Bile acids target an exposed cavity in the glucocorticoid receptor modulating receptor self-assembly, chromatin binding and transcriptional activity.
bioRxiv. 2025 May 16:2025.05.13.653693. doi: 10.1101/2025.05.13.653693.
3
Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.
Malays J Med Sci. 2025 Feb;32(1):35-55. doi: 10.21315/mjms-06-2024-452. Epub 2025 Feb 28.
4
Influence of CYP2D6 polymorphisms on tamoxifen side effects in patients with breast cancer.
Clin Transl Oncol. 2025 Apr 11. doi: 10.1007/s12094-025-03908-y.
5
Cardamom extract alleviates tamoxifen-induced liver damage by suppressing inflammation and pyroptosis pathway.
Sci Rep. 2025 Feb 8;15(1):4744. doi: 10.1038/s41598-025-89091-0.
6
Concurrent water T and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequence.
Magn Reson Imaging. 2025 May;118:110355. doi: 10.1016/j.mri.2025.110355. Epub 2025 Feb 5.
7
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?
Endocrinology. 2025 Feb 5;166(3). doi: 10.1210/endocr/bqaf020.
8
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.
Cancers (Basel). 2025 Jan 13;17(2):234. doi: 10.3390/cancers17020234.
9
Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.
Breast Cancer Res. 2024 Nov 26;26(1):163. doi: 10.1186/s13058-024-01919-1.
10
-Ferrocene Derivatives as Potential Therapeutics.
Molecules. 2024 Oct 16;29(20):4903. doi: 10.3390/molecules29204903.
本文引用的文献
1
Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting.
Cancers (Basel). 2022 Sep 24;14(19):4636. doi: 10.3390/cancers14194636.
2
Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer.
Cancer Res. 2022 Oct 4;82(19):3614-3621. doi: 10.1158/0008-5472.CAN-22-0900.
3
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.
Curr Oncol. 2022 Jul 13;29(7):4956-4969. doi: 10.3390/curroncol29070394.
4
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.
Oncologist. 2022 Jul 5;27(7):e597-e600. doi: 10.1093/oncolo/oyac102.
5
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18.
6
Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
BMC Cancer. 2022 May 6;22(1):507. doi: 10.1186/s12885-022-09484-6.
7
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.
Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17.
8
Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review.
Clin Breast Cancer. 2022 Apr;22(3):e362-e373. doi: 10.1016/j.clbc.2021.10.003. Epub 2021 Oct 9.
9
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
10
Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Bioorg Med Chem Lett. 2021 Nov 15;52:128383. doi: 10.1016/j.bmcl.2021.128383. Epub 2021 Sep 27.
Zotero 插件